Exchange: NASDAQ·Updated 07:30 PM EST

YARW News

News
all
press releases
Yarrow Bioscience Announces Participation in November Investor Events
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that members of its executive team will participate in the following upcoming investor conferences...
Business Wire
Yarrow Bioscience Announces Participation in November Investor Events
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that members of its executive team will participate in the following upcoming investor conferences...
Business Wire
More News
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of its previously announced underwritten public offering of 6,634,615 shares of its...
Business Wire
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the pricing of its previously announced underwritten public offering of 5,769,231 shares of its...
Business Wire
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced that it has commenced an underwritten public offering of shares of its common stock or, in lieu of...
Business Wire
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced financial results for the second quarter ended June 30, 2026 and provided business updates. The...
Business Wire
Yarrow Bioscience, Inc. (Yarrow or the Company) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the completion of its merger with VYNE Therapeutics Inc. (VYNE), and the previously announced...
Business Wire

Advertisement|Remove ads.